medicare semaglutide to Cover Weight-Loss Drug Wegovy for Certain Patients 💉 Medicare is making popular

The active drug in Wegovy is semaglutide , a GLP-1 agonist

Mauvais-Jarvis F, Berthold HK, Campesi I, Carrero J-J, Dhakal S, Franconi F, et al

Healthcare providers may consider: Bacterial culture if infection is suspected Temporary discontinuation of semaglutide to assess symptom resolution Referral to allergy/immunology for suspected hypersensitivity reactions For type 2 diabetes patients only, alternative GLP-1 receptor agonist formulations (such as oral semaglutide/Rybelsus) if injection site reactions are recurrent and problematic Patients with confirmed hypersensitivity to semaglutide should not continue the medication

Physicians in Tampa and surrounding areas are familiar with the drug and know how to monitor patients effectively to minimize risks

GLP-1 receptor agonists like semaglutide cause dose-dependent gastrointestinal side effects